Skip to content
Reassurance on Ductal Carcinoma in Situ (DCIS) Treatment De-Escalation

Reassurance on Ductal Carcinoma in Situ (DCIS) Treatment De-Escalation

Get the podcast

BARCELONA—A multicenter nationwide Italian study of patients with ductal carcinoma in situ (DCIS) treated with breast conservative surgery (BCS) and whole breast radiotherapy (RT) has updated risk cri

The Audio Journal of Oncology

BARCELONA—A multicenter nationwide Italian study of patients with ductal carcinoma in situ (DCIS) treated with breast conservative surgery (BCS) and whole breast radiotherapy (RT) has updated risk criteria to help women opt for gentler treatments and avoid toxicities from overtreatment.

At the 2018 European Breast Cancer Conference Icro Meattini MD, Consultant Clinical Oncologist in the Radiation Oncology Department at Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy said: “A diagnosis of DCIS can be frightening but also confusing. Although we know that very few patients will go on to develop invasive cancer we don’t know which ones they will be and so we offer treatments such as surgery and radiotherapy and sometimes hormone therapy.” He discusses the findings of his study with the Audio Journal of Oncology.

Tags

breast-cancerDCISDCIS Treatment De-EscalationDuctal Carcinoma in Situ

Next in EBCC 2018

All 6 interviews

Interview 4 of 6

Breast Cancer: Combined Risk Assessment Prompts Treatment De-Escalation

Breast Cancer: Combined Risk Assessment Prompts Treatment De-Escalation

BARCELONA—Not only was breast conserving therapy safer than mastectomy for most low-risk patients in the large randomized EORTC 10041/BIG 03-04 MINDACT trial reported at the 2018 European Breast Cance

16 April 2018

Related Episodes

Eline Verreck BSc; 2026 EBCC: Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer

Eline Verreck BSc; 2026 EBCC: Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer

Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer An interview with: Eline Verreck BSc, Erasmus University Medical Centre, Surgical Oncology Department, Rotterd

6 Apr 2026
7 min